Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2658
http://purl.obolibrary.org/obo/NCIT_C2658
|
|---|---|
| Preferred Name | Ertumaxomab |
| Definitions |
A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth. Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth. Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate. |
|---|---|
| prefLabel | Ertumaxomab
|
| label | Ertumaxomab
|
| PDQ_Closed_Trial_Search_ID | 38498
|
| code | C2658
|
| Has_Target | |
| prefixIRI | NCIT:C2658
|
| in_subset |
See more
See less
|
| Display_Name | Ertumaxomab
|
| Preferred_Name | Ertumaxomab
|
| FDA_UNII_Code | L5L45YGP1O
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Ertumaxomab
|
| CAS_Registry | 509077-99-0
|
| NCI_Drug_Dictionary_ID | 38498
|
| Legacy Concept Name | Anti-CD3_x_anti-HER-2-neu_Bispecific_Monoclonal_Antibody
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38498
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C1723386
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |